The Edmonton developers of an herbal remedy for colds and flu reported its first profitable year since the biotech company was founded in 1992. CV Technologies’ COLD-fX product accounted for more than 80% of sales, boosting the start-up’s net profit to $150,918 for the year ending September 30. Total sales for FY04 were $6.41 million, an increase of 316% from $1.54 million a year earlier. Q1/05 registered a spectacular $11.3 million in sales, up 542% over Q1/04. In November, CV Technologies announced the Industrial Research Assistance Program would fund a pre-clinical study, in collaboration with McGill Univ, to investigate the effects of CVT-E002 (the active ingredient in COLD-fX) in treating immune deficiency related to cancer....